Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$5.04 - $8.73 $268,430 - $464,959
-53,260 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$6.58 - $10.66 $219,331 - $355,329
33,333 Added 167.28%
53,260 $362,000
Q1 2021

May 17, 2021

BUY
$6.73 - $13.87 $134,108 - $276,387
19,927 New
19,927 $205,000

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Harbourvest Partners LLC Portfolio

Follow Harbourvest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbourvest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Harbourvest Partners LLC with notifications on news.